BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Business Wire
HERZLIYA, Israel--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or metastatic oesophageal squamous cell carcinoma (OESCC) after prior systemic chemotherapy."In Israel, the incidence of cancer continues to rise, with solid tumors representing a substantial health burden and where access to these inhibitors remains limited for the patients. The recent approval of Tevimbra by the Israeli Ministry of Health provides a new, innovative treatment for patients with esophageal squamous cell carcinoma (ESCC), offering renewed hope and potentially improved outcomes for those affected by these challenging malignancies,” said Itzik Mizrahi, Country General Manager of BeiGene Israel. "We are pleased to have received approval in Israel, which represents a significant step forwa
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $288.00 price target on the stock.MarketBeat
- BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk [Yahoo! Finance]Yahoo! Finance
- BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest TalkPR Newswire
- BeiGene Announces Updates to Commercial Leadership TeamBusiness Wire
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024Business Wire
BGNE
Earnings
- 8/7/24 - Beat
BGNE
Sec Filings
- 9/19/24 - Form 4
- 9/17/24 - Form 144
- 9/5/24 - Form 4
- BGNE's page on the SEC website